G1 Therapeutics Культура компании

Dr. Jay C. Strum, Ph.D., has been Chief Scientific Officer at G1 Therapeutics, Inc. since 2009 and served as its President from 2011 to 2014. Dr. Strum has more than 17 years of drug discovery experience. While at GlaxoSmithkline, Dr. Strum led early drug discovery programs in Cancer and Metabolic Diseases and incorporated the use of human adipose-derived stem cells into the drug discovery process under his leadership. He also played a key role in establishing and driving genomics research at GSK through the creation and management of a transnational gene expression department including a Human tissue repository. Dr. Strum has a wide multidisciplinary expertise and has authored over 40 scientific papers, 3 book chapters and is an inventor on 4 patents. Dr. Strum obtained his PhD in Biochemistry from Wake Forest University and received postdoctoral training with Dr. Bob Bell in Molecular Cancer Biology at Duke University and in Molecular Cell Biology at GlaxoWellcome.

Dr. Rajesh K. Malik, M.D., M.B., Ch.B., has been Chief Medical Officer of G1 Therapeutics, Inc. since July 2014. Dr. Malik oversees the advancement of the G1 Therapeutic's lead CDK 4/6 inhibitor, G1T28-1, into a Phase I study for the reduction of chemotherapy-induced myelosuppression. Dr. Malik served as Senior Vice President and Member of Management Board at Agennix AG and as its Chief Medical Officer since January 2007. Dr. Malik served as the Chief Medical Officer of Agennix Incorporated since January 2007. Dr. Malik served as Chief Medical Officer of Adherex Technologies Inc. from September 7, 2004 to January 12, 2007. He has more than 25 years of combined clinical and industry experience to Adherex, was Executive Director at EMD Pharmaceuticals, where he directed the global clinical development strategy for three EMD/Merck KGaA oncology product candidates. Prior to his time at EMD Pharmaceuticals, Dr. Malik served as Associate Director at Bristol-Myers Squibb, where he was responsible for the global clinical development strategy for an oral taxane and for Bristol-Myers pediatric initiatives. From 1993 to 2000, he was an Assistant Professor at the University of Virginia in Charlottesville, VA. He served fellowships at the Children's Hospital of Philadelphia and Duke University Medical Center. Dr. Malik received his M.D. from the University of Sheffield Medical School in the U.K. Dr. Malik completed his medical training in England, earning his Ch.B. from the University of Sheffield Medical School, with post-graduate training in the U.K. and in the USA.

Karenann Makhuli serves as the Vice President, Clinical Operations of G1 Therapeutics, Inc.. Karenann started at G1 Therapeutics, Inc. in Jul of 2018. Karenann currently resides in the Raleigh-Durham, North Carolina Area.

Lex Smith serves as the VP Technical Operations of G1 Therapeutics, Inc.. Lex started at G1 Therapeutics, Inc. in Apr of 2015. Lex currently resides in the Raleigh-Durham, North Carolina Area.

Shannon Morris serves as the Vice President of G1 Therapeutics, Inc.. Shannon started at G1 Therapeutics, Inc. in Apr of 2017. Shannon currently resides in the Raleigh-Durham, North Carolina Area.

John Demaree serves as the Chief Commercial Officer of G1 Therapeutics, Inc.. John started at G1 Therapeutics, Inc. in July of 2018. John currently resides in the Raleigh-Durham, North Carolina Area.

Barclay Phillips serves as the Chief Financial Officer, Senior Vice President of Corporate Development of G1 Therapeutics, Inc.. Barclay started at G1 Therapeutics, Inc. in November of 2017. Barclay currently resides in the Washington D.C. Metro Area.

Andrew Beelen serves as the Senior Director, Clinical Development of G1 Therapeutics, Inc.. Andrew started at G1 Therapeutics, Inc. in April of 2016. Andrew currently resides in the Raleigh-Durham, North Carolina Area.

Terry Murdock serves as the Chief Operating Officer of G1 Therapeutics, Inc.. Terry started at G1 Therapeutics, Inc. in August of 2017. Terry currently resides in the Raleigh-Durham, North Carolina Area.